← Back to Search
The Immune Landscape Of Non‐Small‐Cell Lung Cancer. Utility Of Cytologic And Histologic Samples Obtained Through Minimally Invasive Pulmonary Procedures
Jason Beattie, L. Yarmus, M. Wahidi, P. Rivera, Christopher R Gilbert, F. Maldonado, Kasia Czarnecka, A. Argento, Alexander C. Chen, F. Herth, D. Sterman
Published 2018 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
The success of immune checkpoint inhibitors and the discovery of useful biomarkers to predict response to these agents is shifting much of the focus of personalized care for non-small cell lung cancer towards harnessing the immune response. With further advancement, more effective immunotherapy options will emerge along with more useful biomarkers. Paradoxically, minimally invasive small biopsy and cytology specimens have become the primary method for diagnosis of patients with advanced disease, as well for initial diagnosis and staging in earlier stage disease. For the benefit of these patients, we will continue to learn how to do more with less. In this perspective, we review aspects of immunobiology that underlie the current state of the art of existing and emerging immunologic biomarkers that hold potential to enhance the care of patients with non-small cell lung cancer. We address practical considerations for acquiring patient samples that accurately reflect disease immune status. We also propose a paradigm shift wherein the most important sample types that need to be proven in pioneering basic science and translation work and subsequent clinical trials are the specimens most often obtained clinically.
This paper references
ALK testing with FISH
Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a Th17 phenotype
L. Segal (2016)
Transthoracic needle biopsy.
Katherine R. Birchard (2011)
Monitoring immune-checkpoint blockade: response evaluation and biomarker development
M. Nishino (2017)
Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses
Y. Lavin (2017)
Reduced Tumour Proportion Scores for Programmed Cell Death Ligand 1 in Stored Paraffin Tissue Sections.
Y. Sato (2018)
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.
M. Maio (2015)
Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
J. McLaughlin (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
R. Herbst (2016)
Immature myeloid cells and tolerogenic cytokine profile in lung adenocarcinoma metastatic lymph nodes assessed by endobronchial ultrasound
António Bugalho (2015)
Clinical significance of defective dendritic cell differentiation in cancer.
B. Almand (2000)
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
Clinical significance of the frequency of regulatory T cells in regional lymph node lymphocytes as a prognostic factor for non-small-cell lung cancer.
T. Hanagiri (2013)
FDA grants accelerated approval to pembrolizumab for fi rst tissue / site agnostic indication
SnapShot: Immune Checkpoint Inhibitors.
Gabriel Abril-Rodriguez (2017)
Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells.
B. Ruffell (2014)
High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes
R. van de Ven (2017)
Test Feasibility of Next-Generation Sequencing Assays in Clinical Mutation Detection of Small Biopsy and Fine Needle Aspiration Specimens.
G. Zheng (2016)
Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer
Christine Feig (2013)
Relationship of baseline tumoral IFNγ mRNA and PD-L1 protein expression to overall survival in durvalumab-treated NSCLC patients.
B. Higgs (2016)
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
S. Koyama (2016)
Technical aspects of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Technical Guideline - March 2017.
M. Pólkowski (2017)
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
M. Marzec (2008)
PL 03.03 Blueprint 2: PD-L1 Immunohistochemistry Comparability Study in Real-Life, Clinical Samples
M. Tsao (2017)
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
V. Kumar (2016)
First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer
D. Carbone (2017)
Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing.
W. Travis (2011)
Dual biological effects of the cytokines interleukin-10 and interferon-γ
C. Wilke (2011)
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
M. Lommatzsch (2018)
Detection of PD-L 1 in circulating tumor cells and white blood cells from patients with advanced non-small cell lung cancer
M. Ilie (2017)
PD‐L1 expression in non‐small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens
J. J. Heymann (2017)
Use of the 22C3 anti–programmed death‐ligand 1 antibody to determine programmed death‐ligand 1 expression in cytology samples obtained from non–small cell lung cancer patients
M. Ilié (2018)
Physicians evidence - based clinical practice guidelines
LA Torre (2013)
Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer
M. Ilié (2018)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
J. Taube (2012)
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
N. Rizvi (2015)
513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study
G. Giaccone (2015)
Intratumor heterogeneity: evolution through space and time.
C. Swanton (2012)
Assessment of the technical performance of the flexible 19-gauge EUS-FNA needle.
S. Varadarajulu (2012)
Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.
N. Thomas (2013)
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
N. McGranahan (2016)
EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer.
Rie Sakakibara (2017)
[Transthoracic needle biopsy of the lung].
W. Quarz (1970)
Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer
L. Gandhi (2018)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
R. Arceci (2012)
Cancer Neoantigens and Applications for Immunotherapy
A. Desrichard (2015)
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy.
C. Alix-Panabières (2016)
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
J. Zhang (2014)
Clinical signi fi cance of the frequency of regulatory T cells in regional lymph node lymphocytes as a prognostic factor for non - small - cell
A Mohos (2013)
IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.
D. Munn (2016)
Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy
Thomas J. Gniadek (2017)
Accumulation of Foxp3+ T Regulatory Cells in Draining Lymph Nodes Correlates with Disease Progression and Immune Suppression in Colorectal Cancer Patients
Liufu Deng (2010)
Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).
N. Rizvi (2015)
Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
N. Rizvi (2016)
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
Elza C. de Bruin (2014)
Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches
Jeff Kamta (2017)
Histologic diagnosis of pancreatic masses using 25-gauge endoscopic ultrasound needles with and without a core trap: a multicenter randomized trial.
K. Kamata (2016)
Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?
K. Kerr (2015)
Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis
S. Blom (2017)
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
A. Calles (2015)
Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?
C. Lazzari (2018)
EUS-guided fine-needle tissue acquisition by using a 19-gauge needle in a selected patient population: a prospective study.
A. Larghi (2011)
Evaluation of the adequacy and diagnostic accuracy of the histology samples obtained with a newly designed 19-gauge EUS histology needle.
J. Iglesias-Garcia (2014)
EUS - guided fi ne - needle tissue acquisition by using a 19 - gauge needle in a selected patient population : a prospective study
J Iglesias-Garcı́a (2011)
Concurrent fine needle aspirations and core needle biopsies: a comparative study of substrates for next-generation sequencing in solid organ malignancies
S. Roy-Chowdhuri (2017)
MA09.03 Cisplatin/Pemetrexed + Durvalumab +/- Tremelimumab in Pts with Advanced Non-Squamous NSCLC: A CCTG Phase IB Study - IND.226
R. Juergens (2017)
Guideline for the Acquisition and Preparation of Conventional and Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Specimens for the Diagnosis and Molecular Testing of Patients with Known or Suspected Lung Cancer
E. H. V. D. Van der Heijden (2014)
Imaging Biomarkers in Immunotherapy
R. Juergens (2016)
PD-L1 biology in response to chemotherapy in vitro and in vivo in ovarian cancer
S. Grabosch (2015)
Abstract 655: Development of IHC staining protocols for assessment of PD-L1 expression in cytological samples
Christine Boyiddle (2017)
The Immune Landscape of Cancer
V. Thórsson (2018)
Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers.
J. Guan (2017)
A Phase II Study of Tri-weekly Low-dose Nab-paclitaxel Chemotherapy for Patients with Advanced Gastric Cancer
S. Sato (2018)
Immune checkpoint blockade: a common denominator approach to cancer therapy.
S. Topalian (2015)
Cytologic‐histologic correlation of programmed death‐ligand 1 immunohistochemistry in lung carcinomas
Eleanor Russell-Goldman (2018)
Coordinated regulation of myeloid cells by tumours
D. Gabrilovich (2012)
Endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA): An overview and update for the cytopathologist
P. VanderLaan (2014)
Comparison of 22G reverse-beveled versus standard needle for endoscopic ultrasound-guided sampling of solid pancreatic lesions
A. Alatawi (2015)
Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan (2018)
Global cancer statistics, 2012
L. Torre (2015)
Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer.
Shinkichi Takamori (2017)
Immune cell profile of sentinel lymph nodes in patients with malignant melanoma – FOXP3+ cell density in cases with positive sentinel node status is associated with unfavorable clinical outcome
Anita Mohos (2012)
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
D. Shin (2017)
Pan-cancer analysis of the extent and consequences of intratumor heterogeneity
Noemi Andor (2016)
Comparison of 22-gauge aspiration needle with 22-gauge biopsy needle in endoscopic ultrasonography-guided subepithelial tumor sampling
G. Kim (2014)
Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
A. Alberg (2013)
Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both.
J. Woodcock (2017)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
H. Borghaei (2015)
PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?
Vanda F Torous (2018)
Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed?
L. Yarmus (2013)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
D. Le (2015)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
D. Le (2017)
Pembrolizumab versus Ipilimumab in Advanced Melanoma.
C. Robert (2015)
The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System
Edmund K. Moon (2017)
Biomarkers for immune checkpoint inhibitors: The importance of tumor topography and the challenges to cytopathology
D. P. Clark (2018)
AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future.
A. Vachani (2017)
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
S. Topalian (2016)
Real-time endobronchial ultrasound-guided transbronchial needle aspiration in mediastinal staging of non-small cell lung cancer: how many aspirations per target lymph node station?
H. S. Lee (2008)
Cisplatin / pemetrexed 1 durvalumab 1 / 2 tremelimumab in patients with advanced non - squamous NSCLC : a CCTG phase IB study - IND . 226
R Juergens (2017)
Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98.
S. Loi (2013)
Applications of immunohistochemistry
Jeyapradha Duraiyan (2012)
Multicenter French harmonization study for PD - L 1 IHC testing in non - small cell lung cancer
J Adam (2018)
Checkpoint Blockade in Lung Cancer and Mesothelioma
L. Lievense (2017)
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway.
V. Boussiotis (2016)
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.
L. Deng (2014)
Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer
A. Mansfield (2016)
Expression of programmed death ligand-1 on tumor cells varies pre and post chemotherapy in non-small cell lung cancer
J. Sheng (2016)
Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas.
S. Kim (2017)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
J. Brahmer (2015)
The tumor‐draining lymph node as an immune‐privileged site
D. Munn (2006)
Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.
S. Kitazono (2015)
Classifying Cancers Based on T-cell Infiltration and PD-L1.
M. Teng (2015)
Physicians Evidence-Based Clinical Practice Development : American College of Chest Thrombolytic Therapy Guideline Methodology for Antithrombotic and
H. Schünemann (2008)
Comparison of 21‐gauge and 22‐gauge aspiration needle during endobronchial ultrasound‐guided transbronchial needle aspiration
T. Nakajima (2011)
Heterogeneity of Tumor and Immune Cell PD‐L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples
D. Casadevall (2017)
Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer
A. Mansfield (2015)
Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer.
S. Antonia (2016)
4PPD-L1 in NSCLC cytology
M. Kovačević (2017)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
M. Reck (2016)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
A. Rittmeyer (2017)
Elements of cancer immunity and the cancer–immune set point
D. Chen (2017)
Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors.
Hélène Salmon (2012)
Comprehensive analysis of the clinical immuno-oncology landscape
J. Tang (2018)
Tumour heterogeneity in the clinic
P. Bedard (2013)
Development of IHC staining protocols for assessment of PD - L 1 expression in cytological samples [ abstract ]
C Boyiddle (2017)
List of cleared or approved companion diagnostic devices ( in vitro and imaging tools )
Original Article Relationship of Fas, FasL, p53 and bcl-2 expression in human non-small cell lung carcinomas
Y. Li (2015)
IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade
M. Ayers (2017)
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
Programmed Death Ligand-1 Immunohistochemistry--A New Challenge for Pathologists: A Perspective From Members of the Pulmonary Pathology Society.
Lynette M. Sholl (2016)
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
J. Michot (2016)
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
D. Rimm (2017)
Integrating liquid biopsies into the management of cancer
G. Siravegna (2017)
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
R. Schreiber (2011)
Comparison of Four PD‐L1 Immunohistochemical Assays in Lung Cancer
S. Hendry (2018)
PD - L 1 in NSCLC cytology . ELCC 2017
M Kovacevic (2017)
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
A. Investigators (2018)
PL04a.03: Durvalumab in ≥3rd-Line Locally Advanced or Metastatic, EGFR/ALK Wild-Type NSCLC: Results from the Phase 2 ATLANTIC Study
M. Garassino (2017)
T cell exclusion, immune privilege, and the tumor microenvironment
J. Joyce (2015)
Improvement of cellularity on cell block preparations using the so‐called tissue coagulum clot method during endobronchial ultrasound‐guided transbronchial fine‐needle aspiration
Rex Chin Wei Yung (2012)
Comparison of 22C3 PD‐L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer
C. Li (2017)
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
B. Routy (2018)
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
A. Parsa (2007)
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
Rikke B. Holmgaard (2013)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
C. Langer (2016)
Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer.
W. Pao (2018)
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
A. Kamphorst (2017)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
N. Lindeman (2018)
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
C. Nicolazzo (2016)
Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade
M. Postow (2018)
EGFR and KRAS mutations in lung carcinoma
Shahreen Billah (2011)
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
L. Zitvogel (2018)
PD-1 and PD-1 ligands: from discovery to clinical application.
T. Okazaki (2007)
Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
M. Rivera (2013)
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
J. Adam (2018)
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer
M. Ratcliffe (2017)
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Enfu Hui (2017)
IFN-g – related mRNA profile predicts clinical response to PD-1 blockade
M. Ayers (2019)
PD - 1 blockade in tumors with mismatch - repair de fi ciency
DT Le (2015)
Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer.
P. Tomasini (2018)
Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival
L. Morris (2016)
PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability
E. Munari (2017)
Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.
M. Ilié (2016)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
R. Herbst (2014)
The immunobiology of cancer immunosurveillance and immunoediting.
Gavin P Dunn (2004)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
L. Fehrenbacher (2016)
P1.07-016 Comparison of PD-L1 Immunohistochemical Staining between EBUS-TBNA and Resected Non-Small Cell Lung Cancer Specimens
K. Sakata (2017)
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
M. Hellmann (2018)
Regulation of tumor metastasis by myeloid-derived suppressor cells.
T. Condamine (2015)
This paper is referenced by
Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?
S. Heeke (2018)
IL-17C-mediated innate inflammation decreases the response to PD-1 blockade in a model of Kras-driven lung cancer
F. Ritzmann (2019)
Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Yaqi Li (2019)
Bronchoscopic tissue yield for advanced molecular testing: are we getting enough?
P. Tajarernmuang (2020)
Lessons for Precision Medicine from Lung Cancer
Brett Bade (2020)
Programmed Death Ligand 1 Testing of Endobronchial Ultrasound–guided Transbronchial Needle Aspiration Samples Acquired For the Diagnosis and Staging of Non–Small Cell Lung Cancer
A. Smith (2019)
Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for PD-L1 Testing In Non-Small Cell Lung Cancer.
Fabio Perrotta (2020)
Increased Plasma Cells and Decreased B-cells in Tumor Infiltrating Lymphocytes are Associated with Worse Survival in Lung Adenocarcinomas
H. E. Lee (2020)
Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women
Tess O’Meara (2019)